Posts By :

Michael

Lysogene releases results from June 24,2022, ordinary and extraordinary annual general meeting. Shareholders approved all proposed resolutions.
Lysogene releases results from June 24,2022, ordinary and extraordinary annual general meeting. Shareholders approved all proposed resolutions. 150 150 Lysogene

  Paris, France —27 June 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS),…

Lysogene Annual Ordinary and Extraordinary General Meeting of 24 June 2022 Availability of the Preparatory Documents
Lysogene Annual Ordinary and Extraordinary General Meeting of 24 June 2022 Availability of the Preparatory Documents 150 150 Lysogene

  Paris, France —03 June 2022 at 6:00 pm CET — Lysogene (FR0013233475 – LYS),…

Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting 150 150 Lysogene

• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2022 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Start Typing